



Biogerontology

Research Foundation

Prevent. Restore. Preserve.

The **Biogerontology Research Foundation** is the UK's leading non-profit foundation specifically focused on Longevity and on expediting the coming paradigm shift from disease treatment to personalized precision prevention. It was the main initial donor that provided financial and organisational support to Longevity International UK for the purpose of establishing the APPG for Longevity. It was also actively involved in the successful initiative of adding a new extension code for "ageing-related diseases" accepted in 2018 by the World Health Organization during the last revisions of its International Classification of Diseases framework.

The Biogerontology Research Foundation has been working to develop the UK's Longevity Industry and the field of Geroscience (The Science of Longevity) to a level of mainstream prominence and recognition since its inception in 2008, nearly a decade before the Longevity Industry rose to its current state of acceptance by the mainstream investors, the global scientific community, the public and the media landscape. While the topic of Longevity is now accepted by even the most conservative industry, scientific and media professionals, it took tireless years of work to achieve, and the Biogerontology Research Foundation has been on the forefront of these developments.

Provided Financing for Initial Scope of Activities of the All-Party Parliamentary Group for Longevity

Produced the First Ever Longevity Industry Landscape Overview Analytical Reports

Succeeded in Having the World Health Organization Add New Code for "Ageing Related" Diseases

Opportunities for Cooperation & Collaboration

The Biogerontology Research Foundation is interested in cooperation, collaboration and initiating dialogue from a number of relevant organizations actively involved in UK governance, ranging from government ministries, agencies and departments, to relevant policy-focused NGOs and think-tanks,, and other relevant organizations in order to facilitate the optimized development of the nation's Longevity politics and governance sphere.

In order to move forward with its expanded scope of activities in the realms of Longevity policy, politics, governance and synergetic industry development, the Biogerontology Research Foundation is actively seeking donations from key institutional and individual sponsors that are keen to see the United Kingdom manifest its latent strengths and prospects, and become the leading Longevity nation that it has the potential to be.

Driving Forward UK Longevity Policy Sphere and the Shift from Treatment to Prevention

The foundation is also interested in collaboration, cooperation, sponsorship and the development of joint initiatives with relevant organizations in the domains of geroscience, the economics of ageing and Longevity policy, politics and governance.

The Biogerontology Research Foundation has a strong history of cross-sector collaboration that includes projects on the development of actionable biomarkers of ageing and the application of Artificial Intelligence for ageing research, on interfacing with international policy organizations and with financial institutions on economic reform to transform the problem of ageing population into the opportunity of Healthy Longevity. It is actively and proactively seeking out additional opportunities for collaboration, cooperation and the launch of joint initiatives in the domains of Longevity policy, politics, and scientific R&D.

BOARD OF TRUSTEES



Dmitry Kaminskiy
MANAGING TRUSTEE
 Dmitry Kaminskiy is the Founder of Aging Analytics Agency, Managing Partner of Deep Knowledge Ventures, and a prominent Longevity Investor and Thought-Leader.



João Pedro de Magalhães
TRUSTEE
 João Pedro de Magalhães is a Portuguese microbiologist. His lab at the University of Liverpool studies aging through both computational and experimental approaches. His ultimate goal is to cure human aging.



Jim Plante
TRUSTEE
 Jim Plante is an investor and technology leader. His work has helped the companies reach dominant positions in their industries regarding both value and offering best-of-breed offerings.



Richard Faragher
TRUSTEE
 Richard Faragher is Professor of Biological Gerontology at the University of Brighton and past Chair of the British Society for Research on Ageing, the International Association of Biomedical Gerontology and the American Aging Association.



Jim Mellon
TRUSTEE
 Jim Mellon, the British billionaire ex-fund manager who became a convert to the emerging science of anti-ageing a few years ago, and has decided to pour his money into his own biotech ventures.

Longevity Industry in UK Landscape Q4 2018

Personalised Medicine

**Companies - 260
 Investors - 250
 Non-Profits - 50
 Research Centres - 25**

Investors
Companies
Non-Profits

AgeTech

Research Labs

Preventive Medicine

Regenerative Medicine

